Immix's NXC-201 hits 95% complete response rate ahead of September update
NEXICART-2's interim data show 19 of 20 evaluable AL amyloidosis patients converted to complete response, with the next update due in September testing whether that rate holds as more patients mature.
Executive Summary
- Immix Biopharma's CAR-T therapy NXC-201 has driven nearly all evaluable patients in an ongoing trial to complete response, extending a signal the company first showed at a hematology conference.
- The company is using this interim signal to justify moving toward a randomized, registrational trial in newly diagnosed patients rather than only relapsed disease.
- No other industry-sponsored trial tests a BCMA-directed CAR-T specifically in relapsed or refractory AL amyloidosis, leaving NXC-201 without a direct comparator in this indication even as BCMA-targeted therapies mature in multiple myeloma.
- A September update will show whether the complete response rate holds as the evaluable population grows and whether durability continues as follow-up lengthens.
The update
Immix disclosed on May 21, 2026 that all four minimal residual disease (MRD)-negative patients presented at the American Society of Hematology meeting in December 2025 have since converted to complete response, bringing the trial's complete response rate to 95%, or 19 of 20 patients. All complete responses were reached within one year of dosing, and the company said no patient who reached complete response has relapsed to date. Every subsequently enrolled patient with available MRD data tested negative at one month post-treatment. Immix said the next NEXICART-2 update is expected in late September 2026. ImmixImmix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory ...May 21, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The trial
NEXICART-2 (NCT06097832) is a Phase 1/2 study of NXC-201, a BCMA-targeted CAR-T cell therapy administered intravenously, in adults with relapsed or refractory AL amyloidosis who have received at least one prior line including a CD38 antibody and a proteasome inhibitor. The trial targets 40 patients and lists a primary completion date of December 1, 2026, after that date was pushed back one year from an original December 2025 target in April 2024. The registered primary endpoints are treatment-related adverse events, adverse events by severity, and confirmation of the maximum tolerated dose and recommended Phase 2 dose, meaning the trial itself is registered to test tolerability and dosing rather than complete response as a formal primary measure. Secondary endpoints cover the percentage of patients with hematologic and organ response. NCT06097832Study of NXC-201 CAR-T in Patients With Light Chain (AL) AmyloidosisNCT06097832
The stake
Gabriel Morris, Immix's President and Chief Financial Officer, said the company plans to present 1-year follow-up data by the end of March 2027, which the company said it expects will support a Biologics License Application submission and commercial launch. The interim result comes from a heavily pretreated population, with a median of four prior lines of therapy, and the company frames NXC-201 as a potential one-time treatment against a disease that otherwise requires roughly two years of ongoing therapy. NXC-201 already holds FDA Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations, along with Orphan Drug Designation from the FDA and the European Medicines Agency. ImmixImmix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory ...May 21, 2026
The competitive field
Among industry-sponsored trials specifically targeting BCMA in relapsed or refractory AL amyloidosis, NEXICART-2 is the only one in clinical testing; the nearest comparator identified in the broader competitive landscape is Regeneron's bispecific antibody linvoseltamab, which is being studied in systemic light chain amyloidosis but uses a different modality. Within the wider BCMA-targeted landscape, most competing programs, including ciltacabtagene autoleucel and idecabtagene vicleucel, are tested in multiple myeloma rather than AL amyloidosis, and none share NXC-201's specific disease population. That leaves NXC-201 without a resolved same-indication, same-target precedent to benchmark its complete response rate against, and the September update becomes the mechanism by which the field will judge whether a CAR-T approach can hold up in this narrower population as enrollment grows.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.